192 related articles for article (PubMed ID: 8761306)
1. The oncoprotein P75gag-v-erbA represses thyroid hormone induced transcription only via response elements containing palindromic half-sites.
Wahlström GM; Harbers M; Vennström B
Oncogene; 1996 Aug; 13(4):843-52. PubMed ID: 8761306
[TBL] [Abstract][Full Text] [Related]
2. Requirements for repression of retinoid X receptor by the oncoprotein P75gag-v-erbA and the thyroid hormone receptors.
Wahlström GM; Vennström B
Mol Endocrinol; 1998 May; 12(5):645-53. PubMed ID: 9605927
[TBL] [Abstract][Full Text] [Related]
3. A choice between transcriptional enhancement and repression by the v-erbA oncoprotein governed by one nucleotide in a thyroid hormone responsive half site.
Andersson ML; Vennström B
Oncogene; 2000 Jul; 19(32):3563-9. PubMed ID: 10951561
[TBL] [Abstract][Full Text] [Related]
4. V-erbA requires auxiliary proteins for dominant negative activity.
Hermann T; Hoffmann B; Piedrafita FJ; Zhang XK; Pfahl M
Oncogene; 1993 Jan; 8(1):55-65. PubMed ID: 8093812
[TBL] [Abstract][Full Text] [Related]
5. c-ErbA, but not v-ErbA, competes with a putative erythroid repressor for binding to the carbonic anhydrase II promoter.
Rascle A; Ghysdael J; Samarut J
Oncogene; 1994 Oct; 9(10):2853-67. PubMed ID: 7916146
[TBL] [Abstract][Full Text] [Related]
6. Dimerization of v-erbA on inverted repeats.
Zubkova I; Subauste JS
Biochem Biophys Res Commun; 2002 May; 294(1):35-41. PubMed ID: 12054736
[TBL] [Abstract][Full Text] [Related]
7. Leukemic transformation by the v-ErbA oncoprotein entails constitutive binding to and repression of an erythroid enhancer in vivo.
Ciana P; Braliou GG; Demay FG; von Lindern M; Barettino D; Beug H; Stunnenberg HG
EMBO J; 1998 Dec; 17(24):7382-94. PubMed ID: 9857194
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of transformation by v-ErbA: substitution for steroid hormone receptor function in self renewal induction.
Bauer A; Ulrich E; Andersson M; Beug H; von Lindern M
Oncogene; 1997 Aug; 15(6):701-15. PubMed ID: 9264411
[TBL] [Abstract][Full Text] [Related]
9. The v-ErbA oncoprotein quenches the activity of an erythroid-specific enhancer.
Braliou GG; Ciana P; Klaassen W; Gandrillon O; Stunnenberg HG
Oncogene; 2001 Feb; 20(7):775-87. PubMed ID: 11314012
[TBL] [Abstract][Full Text] [Related]
10. Identification of DNA binding sites for the V-erbA oncoprotein, the viral homolog to thyroid hormone receptor alpha.
Harbers M; Wahlström GM; Vennström B
J Steroid Biochem Mol Biol; 1998 Nov; 67(3):181-91. PubMed ID: 9879977
[TBL] [Abstract][Full Text] [Related]
11. Targeting of N-CoR and histone deacetylase 3 by the oncoprotein v-erbA yields a chromatin infrastructure-dependent transcriptional repression pathway.
Urnov FD; Yee J; Sachs L; Collingwood TN; Bauer A; Beug H; Shi YB; Wolffe AP
EMBO J; 2000 Aug; 19(15):4074-90. PubMed ID: 10921888
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the DNA-binding and dominant negative activity of v-erbA homodimers.
Subauste JS; Koenig RJ
Mol Endocrinol; 1998 Sep; 12(9):1380-92. PubMed ID: 9731706
[TBL] [Abstract][Full Text] [Related]
13. Requirement for the C-terminal domain of the v-erbA oncogene protein for biological function and transcriptional repression.
Forrest D; Muñoz A; Raynoschek C; Vennström B; Beug H
Oncogene; 1990 Mar; 5(3):309-16. PubMed ID: 1969136
[TBL] [Abstract][Full Text] [Related]
14. The v-erbA oncogene requires cooperation with tyrosine kinases to arrest erythroid differentiation induced by ligand-activated endogenous c-erbA and retinoic acid receptor.
Schroeder C; Gibson L; Beug H
Oncogene; 1992 Feb; 7(2):203-16. PubMed ID: 1347913
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor displays DNA binding and transactivation as a heterodimer with the retinoid X receptor, but not with the thyroid hormone receptor.
Thompson PD; Hsieh JC; Whitfield GK; Haussler CA; Jurutka PW; Galligan MA; Tillman JB; Spindler SR; Haussler MR
J Cell Biochem; 1999 Dec; 75(3):462-80. PubMed ID: 10536369
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing nuclear receptors in transcriptional repression.
Burcin M; Köhne AC; Runge D; Steiner C; Renkawitz R
Semin Cancer Biol; 1994 Oct; 5(5):337-46. PubMed ID: 7849262
[TBL] [Abstract][Full Text] [Related]
17. Regulation of H1(0) gene expression by nuclear receptors through an unusual response element: implications for regulation of cell proliferation.
Bouterfa HL; Piedrafita FJ; Doenecke D; Pfahl M
DNA Cell Biol; 1995 Nov; 14(11):909-19. PubMed ID: 7576177
[TBL] [Abstract][Full Text] [Related]
18. Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product.
Sap J; Muñoz A; Schmitt J; Stunnenberg H; Vennström B
Nature; 1989 Jul; 340(6230):242-4. PubMed ID: 2569164
[TBL] [Abstract][Full Text] [Related]
19. Modulation of normal erythroid differentiation by the endogenous thyroid hormone and retinoic acid receptors: a possible target for v-erbA oncogene action.
Schroeder C; Gibson L; Zenke M; Beug H
Oncogene; 1992 Feb; 7(2):217-27. PubMed ID: 1347914
[TBL] [Abstract][Full Text] [Related]
20. p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor.
De Luca A; Severino A; De Paolis P; Cottone G; De Luca L; De Falco M; Porcellini A; Volpe M; Condorelli G
Biochem J; 2003 Feb; 369(Pt 3):477-84. PubMed ID: 12371907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
